Form 4: Nuvation Bio CSO Sells Shares Under 10b5-1 Plan

Nuvation Bio's Chief Scientific Officer, Gary Hattersley, exercised stock options and subsequently sold 100,000 Class A Common Stock shares as part of a pre-arranged 10b5-1 plan.

Summary

• Gary Hattersley, Chief Scientific Officer of Nuvation Bio Inc., executed a transaction on October 27, 2025.
• Hattersley acquired 100,000 shares of Class A Common Stock by exercising stock options at a price of $1.74 per share.
• Immediately following the option exercise, Hattersley sold 100,000 shares of Class A Common Stock at a weighted-average price of $5.0246 per share.
• The sales were conducted pursuant to a Rule 10b5-1 trading plan established on June 24, 2024.
• The shares were sold within a price range of $5.00 to $5.08.
• After these transactions, Hattersley's direct beneficial ownership of the 100,000 shares involved in this specific report is 0, but he still holds 298,935 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While an executive selling shares can sometimes be viewed negatively, the transaction was pre-arranged under a 10b5-1 plan, indicating a planned financial event rather than a reaction to new company developments. The exercise of options also reflects the executive realizing value from their compensation.

Positives

• The exercise of stock options by a Chief Scientific Officer indicates a realization of value from previously granted equity incentives.
• The transaction resulted in a significant profit for the reporting person, with shares acquired at $1.74 and sold at an average of $5.0246.

Negatives

• The sale of shares by a key executive, even if pre-arranged, could be perceived as a reduction in direct equity exposure to the company.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This transaction is a routine insider trading report for an executive exercising stock options and selling shares, often seen across various industries, particularly in biotechnology where equity compensation is common. The use of a 10b5-1 plan is a standard practice for executives to manage personal finances while avoiding accusations of trading on material non-public information.

Comparison to Industry Standards

• The use of a 10b5-1 plan for executive stock sales is a common corporate governance practice, aligning with industry standards for managing insider transactions transparently.
• The profit realized from the option exercise and sale is typical for executives whose companies have seen stock price appreciation since their options were granted.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale of shares by a CSO might be viewed with slight caution, but the 10b5-1 plan mitigates concerns about opportunistic selling. The transaction itself does not directly impact company operations or strategy.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

This Form 4 filing reports a routine, pre-arranged insider transaction (option exercise and sale under a 10b5-1 plan) by a Chief Scientific Officer. Such transactions are generally not considered significant drivers for a 'buy' or 'sell' recommendation as they reflect personal financial planning rather than a change in the company's fundamental outlook or a strong signal about its future performance. Therefore, a 'hold' recommendation is appropriate, as this specific filing does not provide new information warranting a change in investment thesis.

Keywords

Nuvation Bio, NUVB, Gary Hattersley, Chief Scientific Officer, CSO, Form 4, SEC filing, stock options, insider trading, 10b5-1 plan, equity sale, beneficial ownership